Perspective Therapeutics, Inc.
CATXDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
How CATX's past catalysts played out
[203Pb]VMT-α-NET
Neuroendocrine Tumors Unresectable
[203Pb]VMT01
Recurrent Melanoma (Skin)
[203Pb]Pb-PSV359
Pancreatic Ductal Adenocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
[203Pb]VMT-α-NET | Phase 2 | Neuroendocrine Tumors Unresectable | - | - |
[203Pb]VMT01 | Phase 2 | Recurrent Melanoma (Skin) | - | - |
[203Pb]Pb-PSV359 | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
Frequently asked questions
What is in Perspective Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Perspective Therapeutics, Inc.'s (CATX) pipeline across Phase 2. Its lead program is [203Pb]VMT-α-NET (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Perspective Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Perspective Therapeutics, Inc. (CATX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CATX biotech catalysts?→
Add CATX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Perspective Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.